Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV vaccine in Japanese boys aged 9 to 15 years
2015-004212-37Phase 3
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant in human papillomavirus infection, anogenital warts, anal cancer and 1 more, sponsored by Merck & Co. Primary endpoints: Seroconversion rate for HPV types 6, 11, 16, and 18 and High seroconversion rates after V501 administration.
02
Drugs
human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant
03
Conditions
human papillomavirus infectionanogenital wartsanal canceranal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on 2015-004212-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004212-37.